[The hemostatic system and correction of its impairments, by using the disaggregatory agent ticlopidine and low-molecular-weight heparin in patients with idiopathic fibrosing alveolitis].
The study was undertaken to examine the mechanisms of changes in the plasma and platelet links of hemostasis in patients with idiopathic fibrosing alveolitis in relation to the course of the disease and the possibilities of correcting the detected disorders with antiaggregatory and anticoagulative agents. Sixty-five patients were examined. All the patients were found to have the signs of hypercoagulation and a drastic change in the functional status of platelets. There was a relationship of the severity of impairments of hemocoagulation and platelet aggregation to the nature of a course of the disease. Addition of the antiaggregatory agent ticlopidine to the standard therapy exerted a normalizing impact on the functional status of platelets, which was more pronounced in the progressive course of the disease. The use of the low molecular-weight heparin fraxiparine had a beneficial effect on both components of the hemostatic system, which was more marked in the progressive course of idiopathic fibrosing alveolitis.
Vasil'ev
S N
SN
Stepanian
I E
IE
Kaminskaia
G O
GO
Serebrianaia
B A
BA
Shmelev
E I
EI
D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D013988:Ticlopidine / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D013988:Ticlopidine